SCHEMBL690245

SCHEMBL690245

CCSCCN1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
TSHR P16473 1/20 0.45
HRH3 Q9Y5N1 2/20 0.44
CARM1 Q86X55 1/20 0.39
PRMT6 Q96LA8 1/20 0.39
PRMT8 Q9NR22 1/20 0.39
ALOX15 P16050 1/20 0.38
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
CYP1A2 P05177 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 3/20 0.34
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GAA P10253 1/20 0.34
LTA4H P09960 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19841298 0.98 ALDH1A1 (0.42) ALDH1A1TSHRHRH3CARM1PRMT6
SCHEMBL7753117 0.91 POLB (0.38) ALDH1A1TSHRHRH3CARM1PRMT6
SCHEMBL20389744 0.86 HRH3 (0.52) ALDH1A1TSHRHRH3CARM1PRMT6
SCHEMBL4173915 0.85 HRH3 (0.52) ALDH1A1TSHRHRH3CARM1PRMT6
SCHEMBL8967208 0.85 HRH3 (0.56) ALDH1A1TSHRHRH3MAPTCYP1A2
SCHEMBL13895095 0.84 ALDH1A1 (0.44) ALDH1A1TSHRHRH3CARM1PRMT6
SCHEMBL12055886 0.82 ALDH1A1 (0.50) ALDH1A1TSHRHRH3CARM1PRMT6
SCHEMBL18481175 0.81 PAOX (0.35) ALOX15CYP1A2MEN1KMT2ALMNA
SCHEMBL8967500 0.80 HRH3 (0.44) ALDH1A1TSHRHRH3CARM1PRMT6
SCHEMBL8966776 0.79 HRH3 (0.43) ALDH1A1TSHRHRH3CYP1A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0468434-B1 Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis MERRELL DOW PHARMA (US) 1996-02-28 EP claimed
US-5348964-A Anticholesterol agents or fungicides MERRELL DOW PHARMACEUTICALS INC. (US) 1994-09-20 US claimed
EP-0468434-A1 Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis MERRELL PHARMACEUTICALS INC. (US) 1992-01-29 EP claimed
US-12552807-B2 PCSK9 inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2026-02-17 US disclosed
EP-4470609-A2 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2024-12-04 EP disclosed
EP-3911648-B1 6'-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)-2-PYRIMIDINYL]AMINO]CYCLOPENTYL]AMINO][1(2H),3'-BIPYRIDIN]-2-ONE AS PCSK9 INHIBITOR AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-10-23 EP disclosed
US-20220220122-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2022-07-14 US disclosed
US-11248001-B2 PCSK9 inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2022-02-15 US disclosed
EP-3911648-A2 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2021-11-24 EP disclosed
US-20200291041-A1 PCSK9 Inhibitors and Methods of Use Thereof ASTRAZENECA AB (SE) 2020-09-17 US disclosed
WO-2020150473-A2 PCSK9 INHIBITORS AND METHODS OF USE THEREOF DOGMA THERAPEUTICS, INC. (US) 2020-07-23 WO disclosed
US-5965553-A Squalene synthetase inhibitors PFIZER INC. (US) 1999-10-12 US disclosed
US-5807834-A ANTICHOLESTEROL AGENTS PFIZER INC. (US) 1998-09-15 US disclosed
EP-0814080-A1 Squalene synthetase inhibitors PFIZER INC. (US) 1997-12-29 EP disclosed
WO-1997048701-A1 4,1-BENZOXAZEPINES OR 4,1-BENZOTHIAZEPINES AND THEIR USE AS SQUALENE SYNTHETASE INHIBITORS PFIZER INC. (US) 1997-12-24 WO disclosed
EP-0782451-A1 COMBINATION OF A CHOLESTEROL ABSORPTION INHIBITOR AND A CHOLESTEROL SYNTHESIS INHIBITOR PFIZER INC. (US) 1997-07-09 EP disclosed
WO-1996009827-A2 COMBINATION OF A CHOLESTEROL ABSORPTION INHIBITOR AND A CHOLESTEROL SYNTHESIS INHIBITOR PFIZER INC. (US) 1996-04-04 WO disclosed
EP-0468434-B1 Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis MERRELL DOW PHARMA (US) 1996-02-28 EP disclosed
US-5348964-A Anticholesterol agents or fungicides MERRELL DOW PHARMACEUTICALS INC. (US) 1994-09-20 US disclosed
EP-0468434-A1 Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis MERRELL PHARMACEUTICALS INC. (US) 1992-01-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11248001-B2 PCSK9 inhibitors and methods of use thereof PCSK9, PCSK7, PCSK6 ALDH1A1 4217/4885TSHR 3215/4885HRH3 2495/4885
US-20200291041-A1 PCSK9 Inhibitors and Methods of Use Thereof PCSK9, PCSK7, PCSK6 ALDH1A1 4495/4885TSHR 3197/4885HRH3 2162/4885
US-12552807-B2 PCSK9 inhibitors and methods of use thereof PCSK9, PCSK7, PCSK6 ALDH1A1 4688/4885TSHR 1101/4885HRH3 1126/4885
US-20220220122-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF PCSK9, PCSK7, PCSK6 ALDH1A1 4495/4885TSHR 3197/4885HRH3 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.